What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2
- “The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response”In the company’s words, NCT06514794 on ClinicalTrials.gov
Other drugs for T-cell Acute Lymphoblastic Leukemia
- Autologous BCMA/CD19 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/CD38 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/GPRC5D dual-target CAR-TBeijing Biotech · Phase 1/2
- Autologous CD19/CD20 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous CD19/CD22 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous CD33/CD123 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
Coming up1
- 30 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Dec 2026 | A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | |
| Phase 1Completed | 8 Aug 2024 | A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026